Tatva Chintan Pharma Chem Plans Rs 200 Crore Greenfield Expansion At Dahej-III

Profits Surge On Demand PAT at Rs 16.0 Cr in Q1 FY27, +140.3% YoY; includes exceptional loss of Rs 1.3 Cr. Revenue at Rs 167 Cr in Q1 FY27, +42.9% YoY. EBITDA at Rs 35.1 Cr, +89.8% YoY. EBITDA margin at 21.0% vs 15.8%. Board re-appointed Chintan Shah (MD), Ajay Patel (WTD), and Shekhar Somani (WTD) for 3 years from Feb 2027. Approved greenfield capacity addition of 344 KL at Dahej-III, investment ~Rs 200 Cr over ~21 months. Borrowing limit raised from Rs 300 Cr to Rs 1,000 Cr, subject to shareholder approval.